New EU subcutaneous Orencia approval to help BMS better demonstrate value to payers?
This article was originally published in Scrip
The European Medicines Agency has approved a subcutaneous version of Bristol Myers Squibb's rheumatoid arthritis drug Orencia (abatacept), which could save some hospitals money because it allows for self-administration. But despite the potential savings, it is unclear whether the new formulation will convince payers to choose the product.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.